Non-Animal Models (NAMs) in Practice: Approaches for Preclinical Safety and Efficacy Screening

En este seminario web se tratarán los siguientes temas

UK, US, and EU perspectives on New Approach Methodologies.

Case studies spanning:

Whole blood bioassays.
Isolated primary immune cell assays.
Our ex vivo skin explant platform.
Reconstructed skin models for efficacy and tolerance tests.
Applications of precision cut lung slices for respiratory research without animal testing.

Inscribirse

Date: 2026-10-15

Hora: 11:00 AM (EDT)

Idioma : English

Tasa: Free

Temas: Lab Testing

Oradores: Kelsey Retting, Arnaud Huard, Callum O Kane

Registrar

Lo que aprenderá

Join us on October 15, 2026 (1700 CEST / 1500 UTC) for our live webinar: Non-Animal Models in Practice: Approaches for Preclinical Safety and Efficacy Screening.

In this webinar, we’ll cover:

The history and status of NAMs in EU, UK, and US preclinical testing.
Ex vivo platform data from human blood bioassays.
Dermal safety and efficacy testing without animal models.
Respiratory indication testing using human-relevant alternatives.

Equip your team with a clearer view of where non-animal approaches really stand today, and where they may head next.

Sobre los ponentes

Kelsey Retting

Senior BD Manager, QIMA Life Sciences

Kelsey is a Senior Business Development Manager at QIMA Life Sciences with a PhD in Biological Chemistry from UCLA and a career spanning drug discovery, in vitro pharmacology, and translational research. She has worked across large pharmaceutical companies, biotechnology firms, and start-ups, developing assays and complex 3D tissue-engineered and bioprinted models for disease modeling, compound screening, and preclinical development.

Arnaud Huard

Study Director, QIMA Bioalternatives

Arnaud is a study directeur at QIMA Bioalternatives, specialised in immuno-inflammation research. He achieved a PhD on resolution of inflammation in Frankfurt, followed by two postdocs in Geneva, working on skin inflammation, psoriasis and inflammasome biology, in the context of hyperinflammatory syndrome.

Callum O Kane

Market Segment Lead, QIMA Life Sciences

Callum began his research career at Queen's University Belfast, gaining a PhD in pathogen epigenetics, before joining the Axis Bio science team. He spent five years with Axis, leading cell culture projects and R&D, and acting as study director for in vivo and in vitro research projects, before joining QIMA Life Sciences.

Lecturas complementarias

Acerca de la organización

QIMA, líder mundial en servicios de control de calidad y soluciones de cumplimiento normativo, ayuda a las empresas a fabricar productos en los que los consumidores puedan confiar, ofreciendo servicios de inspección, pruebas de laboratorio, auditoría y certificación. Combinando la experiencia humana sobre el terreno con tecnología inteligente, QIMA da soporte a más de 30.000 empresas en los sectores de Bienes de Consumo, Alimentación y Agroindustria, Cosmética y Cuidado Personal, y Farmacéutica y Biotecnología, en más de 100 países.

Seminarios web relacionados

Ver todos